Join
Live feed
·
NEWSReleasevia Quantisnow
Medicenna Therapeutics Corp. logo

Reported Earlier, Medicenna Therapeutics Doses First Patient In Phase 2 Monotherapy Dose Expansion Portion Of The ABILITY Study Evaluating MDNA11 In Select Types Of Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
MDNA· Medicenna Therapeutics Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MDNA (Medicenna Therapeutics Corp.) and more on Quantisnow.